Literature DB >> 4063975

Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.

P A Andrews, M P Murphy, S B Howell.   

Abstract

We have determined the effect of glutathione (GSH) depletion on the cytotoxicity of three nitrogen mustards, six platinum complexes, and mitomycin C in a human ovarian carcinoma cell line. GSH levels in COLO 316 cells were depleted by exposure of cell monolayers to 0.5 mM D,L-buthionine-S,R-sulfoximine. GSH depletion significantly potentiated the cytotoxicity of L-phenylalanine mustard, chlorambucil, and mechlorethamine as determined by clonogenic assay on plastic plates. The dose modification factors were 2.6, 2.6, and 1.9, respectively. The same level of GSH depletion had a minimal effect on the cytotoxicity of cis-diamminedichloroplatinum(II) (cis-DDP), carboplatin, dichloro(ethylenediamine)platinum(II), 1,2-diaminocyclohexylplatinum(II) malonate, and iproplatin. The dose modification factors of GSH depletion for these drugs were 1.4 or less. trans-Diamminedichloroplatinum(II) was, however, markedly potentiated by GSH depletion with a dose modification factor of 2.7. Mitomycin C was minimally potentiated by GSH depletion. We have also generated cis-DDP-resistant cells from COLO 316 and 2008 human ovarian carcinoma cells by in vitro selection with cis-DDP. These cis-DDP-resistant cells had identical levels of GSH as the parental cells. GSH depletion sensitized these cells only to the same degree as the parental cells and did not reverse the resistant phenotype. Our results indicate that intracellular GSH levels are not an important determinant of the cytotoxicity of cis-platinum(II) or cis-platinum(IV) complexes in COLO 316 and 2008 cells. In addition, altered GSH metabolism does not appear to be a component of the cis-DDP-resistant phenotype in these cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4063975

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Activity and DNA binding of new organoamidoplatinum (II) complexes.

Authors:  T Talarico; D R Phillips; G B Deacon; S Rainone; L K Webster
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum.

Authors:  K Ikeda; K Miura; S Himeno; N Imura; A Naganuma
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

3.  In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.

Authors:  G Chen; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 4.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

5.  In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

Authors:  R D Christen; A P Jekunen; J A Jones; F Thiebaut; D R Shalinsky; S B Howell
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.

Authors:  E Kimura; R E Enns; F Thiebaut; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  The interaction of DNA-targeted platinum phenanthridinium complexes with DNA.

Authors:  J Whittaker; W D McFadyen; G Wickham; L P Wakelin; V Murray
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

8.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

10.  Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

Authors:  S Isonishi; A P Jekunen; D K Hom; A Eastman; P S Edelstein; F B Thiebaut; R D Christen; S B Howell
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.